April 12th 2021
Kerry A. Rogers, MD, discusses the next steps with the triplet combination of obinutuzumab, ibrutinib, and venetoclax in chronic lymphocytic leukemia.
April 9th 2021
Jonathan C. Trent, MD, PhD, discusses the role of avapritinib in PDGFRA exon 18–positive gastrointestinal stromal tumor.
Mei Wei, MD, discusses the risk of interstitial lung disease with fam-trastuzumab deruxtecan-nxki in HER2-positive breast cancer.
Paul M. Barr, MD, discusses the next steps with the combination of umbralisib, ublituximab, and venetoclax in chronic lymphocytic leukemia.
Anna T. Levy, DO, discuses the safety profile and appropriate dosing of cabozantinib in patients with hepatocellular carcinoma.
April 8th 2021
Paul M. Barr, MD, discusses the safety profile of umbralisib plus ublituximab and venetoclax in chronic lymphocytic leukemia.
Erin Murphy, MD, discusses remaining questions with stereotactic body radiotherapy in pediatric sarcoma.
Andre Goy, MD, discusses the clinical implications of CAR T-cell therapy in mantle cell lymphoma.
April 7th 2021
Mazyar Shadman, MD, discusses considerations for BTK inhibitors in the treatment of patients with chronic lymphocytic leukemia.
Nina Shah, MD, discusses the management of CAR T-cell therapy–related toxicities in multiple myeloma.